雾化吸入重组人干扰素α1b治疗小儿毛细支气管炎的临床观察

Clinical Observation of Aerosol Inhalation Recombinant Human Interferon α1b in the Treatment of Bronchiolitis in Children

目的：观察雾化吸入重组人干扰素α1b治疗小儿毛细支气管炎的疗效和安全性。方法：60例毛细支气管炎患儿随机均分为低剂量组、高剂量组和对照组。各组患儿均给予吸痰、化痰、抗感染等常规对症治疗。在此基础上,低剂量组患儿给予重组人干扰素α1b 1~2μg/（kg·次）,加入0.9%氯化钠注射液3 ml中,压缩雾化吸入,每日2次;高剂量组患儿给予重组人干扰素α1b3~4μg/（kg·次）,加入0.9%氯化钠注射液3 ml中,压缩雾化吸入,每日2次;对照组患儿给予病毒唑10~15 mg/（kg·d）,按1∶1的比例加入5%葡萄糖注射液中,静脉滴注,每日1次。各组疗程均为5~7 d。观察各组患儿的临床疗效,咳嗽消失时间、喘息消失时间、肺部啰音消失时间、三凹征消失时间、住院时间及不良反应发生情况。结果：高剂量组患儿咳嗽消失时间、喘息消失时间、肺部啰音消失时间、三凹征消失时间、住院时间均显著短于低剂量组,而低剂量组短于对照组,差异均有统计学意义（P〈0.05）。高剂量组患儿总有效率显著高于低剂量组,而低剂量组高于对照组,差异均有统计学意义（P〈0.05）。各组患儿治疗期间均未见明显不良反应发生。结论：在常规治疗的基础上,雾化吸入重组人干扰素αlb治疗小儿毛细支气管炎疗效和安全性均较好。

OBJECTIVE：To observe the efficacy and safety of aerosol inhalation recombinant human interferon α1b in the treatment of bronchiolitis in children. METHODS：60 children with bronchiolitis were randomly divided into low-dose group,high-dose group and control group. All children were given tracheal suctioning,phlegm dispersing and other symptomatic treatment. Based on it,low-dose group was given recombinant human interferon α1b 1-2 μg/（kg·times）,adding into 3 ml 0.9% Sodium chloride injection,compression aerosol inhalation,twice a day;high-dose group was given recombinant human interferon α1b 3-4 μg/（kg·times）,adding into 3 ml 0.9% Sodium chloride injection,compression aerosol inhalation,twice a day;control group was given ribavirin10-15 mg/（kg·d）,adding into 5% Glucose injection at ratio of 1∶1 by intravenous infusion,once a day. The treatment course for all groups was 5-7 d. Clinical efficacy,disappearance time of cough,respite,rale and three depressions,hospitalization time and incidence of adverse reactions in all groups were observed. RESULTS：Disappearance time of cough,respite,rale and three depressions and hospitalization time in high-dose group were significantly shorter than low-dose group and low-dose group shorter than control group,the differences were statistically significant（P〈0.05）. Total effective rate in high-dose group was significantly higher than low-dose group and low-dose group higher than control group,the differences were statistically significant（P〈0.05）.There were no obvious adverse reactions during treatment. CONCLUSIONS：Based on conventional treatment,both efficacy and safety of aerosol inhalation recombinant human interferon α1b in the treatment of bronchiolitis in children are good.